Company profile

Celularity

Celularity has raised $290M and completed post-IPO capital transactions in 2025. Founded in 2016, Celularity develops placenta-derived allogeneic cell therapies targeting oncology, infectious, and degenerative diseases. Lead candidates include placental NK and stromal cell programs such as CYNK001. Funding has supported clinical trials, manufacturing scale-up, and translational research. Backing from Celgene and United Therapeutics enabled the development of cell banks, regulatory filings, and early human studies to demonstrate safety and efficacy. Celularity’s platform advances scalable, off-the-shelf cell therapeutics with the goal of broad clinical application.

Back to profiles

Quick facts

Total funding: $290M
Founded: 2016

Reach buyers like Celularity on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Celularity
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Celularity.

The 14-day trial ships every feature, no card required.

Start free →